SCHEMBL16645176

SCHEMBL16645176

CC(C)(C)OC(=O)N1CCc2cc(CN3CCN(C(=O)CN4CCOCC4)CC3)ccc2C1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 1/20 0.55
NR1H2 P55055 1/20 0.47
CHRM2 P08172 1/20 0.42
CHRM4 P08173 1/20 0.42
CHRM1 P11229 1/20 0.42
CHRM3 P20309 1/20 0.42
NAMPT P43490 3/20 0.41
ALOX15 P16050 1/20 0.41
TSHR P16473 1/20 0.41
HSD17B10 Q99714 1/20 0.41
HRH3 Q9Y5N1 1/20 0.41
IDO1 P14902 1/20 0.40
TDO2 P48775 1/20 0.40
IDO2 Q6ZQW0 1/20 0.40
BCL2 P10415 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
TMEM97 Q5BJF2 1/20 0.39
SIGMAR1 Q99720 1/20 0.39
KMT2A Q03164 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16645177 0.86 ESR2 (0.50) ESR2NR1H2NAMPTTSHRIDO1
SCHEMBL17969237 0.85 TSHR (0.47) NAMPTALOX15TSHRHSD17B10HRH3
SCHEMBL30368214 0.85 PIK3CA (0.49) ESR2NR1H2NAMPTTSHRHRH3
SCHEMBL25669120 0.85 PIK3CA (0.49) ESR2NR1H2NAMPTTSHRHRH3
SCHEMBL16645225 0.85 ESR2 (0.56) ESR2NR1H2CHRM2CHRM4CHRM1
SCHEMBL16634827 0.84 ESR2 (0.52) ESR2NR1H2IDO1TDO2IDO2
SCHEMBL31013967 0.84 ESR2 (0.63) ESR2NR1H2NAMPTIDO1TDO2
SCHEMBL31013856 0.80 NR1H2 (0.62) ESR2NR1H2NAMPTTMEM97SIGMAR1
SCHEMBL1790282 0.77 HTT (0.53) ESR2NR1H2SMN1; SMN2KMT2AUSP2
SCHEMBL17969240 0.77 NAMPT (0.53) CHRM1NAMPTSMN1; SMN2KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160229835-A1 NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS ELI LILLY AND COMPANY 2016-08-11 US disclosed
US-20160229835-A1 NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS ELI LILLY AND COMPANY 2016-08-11 US disclosed
US-20160229835-A1 NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS ELI LILLY AND COMPANY 2016-08-11 US disclosed
WO-2015054060-A1 NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS ELI LILLY AND COMPANY (US) 2015-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160229835-A1 NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS NAMPT, NAPRT, NNMT ESR2 4495/4885NR1H2 2307/4885CHRM2 4785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.